Trovirdine

Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA) and dGTP as substrate. IC50 value: 7 nM Target: HIV-1 Trovirdine is currently in phase I clinical trials for potential use in thetreatment of AIDS.

Product Specifications

CAS Number

[149488-17-5]

Product Name Alternative

LY300046

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

HIV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Trovirdine.html

Purity

99.43

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

S=C(NCCC1=NC=CC=C1)NC2=NC=C(Br)C=C2

Molecular Formula

C13H13BrN4S

Molecular Weight

337.24

Precautions

H315, H319, H335

References & Citations

[1]Zhang, H. et al. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethylthiazolyl thiourea derivatives trovirdine and MSC-127.|[2]Cantrell, A.S. et al. Phenethylthiazolylthiourea (PETT) compounds as a newclass of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.